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Dendritic cells (DC) play a critical role in the initiation of the
immune response, acting as sentinels in the tissues, reacting to
invading pathogens and then inducing the activation and differ-
entiation of naïve T cells. Since their discovery by Ralph Steinman
in the 1970s, we have learned a great deal about DC biology and
function. Distinct DC subsets exist in specific tissue niches and
within the secondary lymph nodes, and the study of the phenotype
and function of DC subsets in mice and humans has been an area
of great interest. DC influence the immune response by directing
the differentiation of T cells into functional subtypes important
for elimination of the relevant pathogen. DC also contribute to
disease pathogenesis, such as autoimmunity and cancer, through
failures in self-tolerance and promotion of an immunosuppres-
sive environment, respectively. In addition, because of their role
in molding T cell responses, DC have been tested in therapeutic
settings in both autoimmunity and cancer. In this research topic,
11 articles cover many aspects of current DC biology, ranging from
the classification and function of DC subsets, roles of DC in disease
pathogenesis to current use of DC in the therapeutic setting.
The topic begins with two reviews of normal DC function; one
is focused on the important topic of cross-presentation (1) and
the other on human plasmacytoid (p)DC (2). Cross-presentation
is the means by which DC are uniquely able to take up, process,
and present exogenous antigens in MHC class I molecules and
this review (1) describes novel findings on the role of intracel-
lular vesicular traffic in this process and how it is influenced
by inflammatory signals. pDCs were first identified as type 1
interferon-producing cells following acute viral infection and have
also been shown to have tolerogenic properties. The review by
Mathan et al. (2) focuses on interactions between human pDCs
and other cells of the immune system with a particular emphasis
on cell surface proteins that facilitate these interactions.
The next four articles in this research topic are original research
focusing on various aspects of DC function in vivo and in vitro
(3–6). DC maturation is induced by interaction with pathogen-
derived molecules such as LPS, but infections also induce produc-
tion of a large number of cytokines. Work by Hartmann et al. (3)
examined the effects of virally induced cytokines on the matura-
tion and function of human DC. These studies identified a set of
five cytokines that are critical for the induction DC maturation.
In addition, this study emphasizes a systems approach to studying
the complex effects of cytokine-induced DC maturation (3). DC
play an important role in maintaining tolerance to self-antigens
and the second article in this section describes the role of early
IL-10 production in induction of tolerance to a self-antigen (6).
This article builds on the intriguing observation by the same group
that immunization with foreign antigen induces a rapid upregu-
lation of pancreatic enzymes in splenic DC that is correlated with
the induction of immunity. The present article shows that immu-
nization with a self-antigen fails to induce pancreatic enzymes and
demonstrates a role for IL-10 in this phenomenon (6). Work by
Kokulus et al. (5) demonstrates the influence of mild chronic cold
stress on the phenotype and function of DC in normal and tumor-
bearing mice. These studies highlight the importance of regulating
ambient temperature when conducting experiments with experi-
mental animals and the impact of non-physiologic temperature.
Chronic human inflammatory diseases are often characterized by
changes in circulating monocyte and DC populations. The final
article in this section describes a novel flow cytometry panel, using
CD4 as a lineage marker that allows the enumeration of mono-
cyte, DC, and lymphocyte populations in a single panel (4). This
panel was validated in patients with immunodeficiency, cancer,
and inflammatory conditions.
The final group of five reviews highlights the role of DC in
either causing or ameliorating disease (7–11). Autoimmune dis-
eases are characterized by a breakdown of self-tolerance followed
by an immune response that causes damage to normal tissues. DC
play roles at all stages of the autoimmune response and these are
outlined in a review that focuses specifically on type 1 diabetes
(T1D) (11). This review also highlights the potential for using DC
to prevent or treat T1D and discusses the latest clinical trials using
or targeting DC in this disease (11). The second review focuses
on the many types of immunoregulatory DC and their role in
preventing inflammatory conditions such as autoimmunity, trans-
plant rejection, and atopic diseases (9). The last three reviews in
this research topic focus on the therapeutic use of DC as cancer
vaccines. In the first of these reviews, the importance of tertiary
lymphoid structures in the development of effective anti-tumor
immunity is discussed (8). The authors show that injection of DC,
expressing the transcription factor Tbet, into the tumor stimulates
the generation of tertiary lymphoid structures and contributes to
tumor eradication. The second provides an overview of the prepa-
ration, functional characteristics, and use of human DC in cancer
vaccines, with particular emphasis on the culture methods, mat-
uration cocktails, antigen formulation, and routes of delivery that
are currently in use (7). The final review in this research topic
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focuses on the barriers to the generation of effective DC vac-
cines in cancer patients (10). In particular, this review outlines
the challenges posed by immunosuppressive monocyte popula-
tions, prevalent in cancer patients, which impede the generation
of immunostimulatory DC vaccines.
Thus, this research topic provides a timely overview of some of
the recent advances in DC biology and we look forward to many
new developments in this exciting field.
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